RxDoctor Payments Data

Jacob Cockerhan

Registered Nurse · Waterford, MINPI 1922539378

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Indivior Inc. accounts for 68.1% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $335, 3.1 times the $106 reported in 2023. Among registered nurse clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$756in general payments, 2019–2025

Across 36 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$515
  • Johnson & Johnson$75
  • Alkermes, Inc.$61
  • E.r. Squibb & Sons, L.L.C.$45
  • Otsuka America Pharmaceutical, Inc.$17
  • Teva Pharmaceuticals USA, Inc.$15
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$756 in reported general payments places this provider in the 90th percentile of 121 registered nurse providers in Michigan.

See all registered nurse providers in Michigan

Medicare billing

Part B allowed, 2024
$8,920
Medicare patients
54
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate51$163,328
Abilify MaintenaAripiprazole17$51,190
VraylarCariprazine Hcl13$18,743
RexultiBrexpiprazole11$15,769
TrintellixVortioxetine Hydrobromide23$11,912
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl46$8,087
Fluphenazine Hcl23$5,042
Aripiprazole66$3,958
Clozapine63$2,781
Paliperidone ErPaliperidone16$2,177
Oxcarbazepine33$2,062
Trazodone Hcl96$1,775
Divalproex Sodium ErDivalproex Sodium39$1,724
Doxepin Hcl39$1,318
Olanzapine60$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$75$163,32851 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$17$66,95928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 121 registered nurse providers in Michigan.

Other registered nurse in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →